2.. Introduction {#s1}
================

Over 500 million years ago, the vertebrates emerged from their invertebrate ancestor via an evolutionary leap involving two rounds of whole genome duplication (2R-WGD) \[[@RSOB140029C1]--[@RSOB140029C5]\]. Most of the resulting quadruplicated genes and proteins, termed 2R-ohnologues, were lost. However, the few thousand families of two to four 2R-ohnologues that still survive in modern humans are remarkably enriched in signalling molecules. These include families of growth factors, receptors, protein kinases, GTPases and their regulators, ion channels, transcription factors, developmental regulators and proteins that interact transiently with multi-protein complexes, and many of these are also 14-3-3-binding phosphoproteins \[[@RSOB140029C6],[@RSOB140029C7]\]. By contrast, core components of stable multi-protein complexes such as RNA polymerases and the proteasome, and genes that were duplicated by small-scale genomic events after the 2R-WGD, tend not to be 2R-ohnologues \[[@RSOB140029C8],[@RSOB140029C9]\]. These findings indicate that the 2R-WGD provided a selective boost to regulatory systems, which enabled vertebrate life to evolve. However, there appears to be a downside to the vertebrate style of signalling complexity: several studies have highlighted that 2R-ohnologue dysregulations are highly linked to neurodevelopmental and metabolic disorders, and to cancers \[[@RSOB140029C7],[@RSOB140029C10],[@RSOB140029C11]\].

Most cancers rely on a restricted number of 'driver' mutations, which confer cells with selective advantages that promote cancer initiation, progression and metastasis. Some driver mutations inactivate tumour suppressors such as p53, which normally induces growth arrest or apoptosis in stressed cells. Other drivers involve specific gene fusions, or point mutations such as B-Raf^V600E^, K-Ras^G12D^ and N-Ras^Q61R^, which activate oncogenic signalling pathways \[[@RSOB140029C12]--[@RSOB140029C14]\]. At the biochemical level, oncogenic signalling stimulates multiple intracellular changes that together promote the cancer phenotype. Interestingly, many tumour suppressors and oncogenic drivers, including p53, B-Raf and Ras proteins, belong to 2R-ohnologue families \[[@RSOB140029C11]\].

In addition to drivers, cancers can accumulate heavy loads of somatic mutations \[[@RSOB140029C15]\]. Most are considered to be 'passengers' that do not contribute to cancer progression \[[@RSOB140029C16]\]. However, we reasoned that there must be constraints on which mutations are compatible with any given oncogenic driver. If too many of the proteins that enact the downstream functions of an oncogenic driver were to suffer deleterious passenger mutations, the driver would lose its efficacy. Then, the cancer cell lineage would die out or become quiescent unless it acquired a different driver mutation that operates via a different mechanism, which might help explain cancer heterogeneity \[[@RSOB140029C17]--[@RSOB140029C19]\].

This study investigates how somatic mutations in cancers are distributed within families of 2R-ohnologue signalling genes. A general characteristic of 2R-ohnologues is that the domain architectures of the encoded proteins are conserved across each family. Therefore, the broad expectation is for members of a given family to share a high degree of overlap in their core functions. On the other hand, owing to localized sequence changes, family members may differ in their expression patterns, post-translational modifications, regulation by protein kinases, kinetic rates, binding affinities and substrate selectivities \[[@RSOB140029C8],[@RSOB140029C20]--[@RSOB140029C23]\]. We therefore conceptualize each 2R-ohnologue protein family as a multiple-input multiple-output (MIMO) system that integrates different input signals to produce a combined functional output \[[@RSOB140029C7],[@RSOB140029C24]\]. The phenotype of a cell will depend on which combinations of 2R-ohnologues from each family are expressed and engaged by the signalling pathways that operate in any physiological context \[[@RSOB140029C7],[@RSOB140029C24]\].

Stemming from the MIMO signal-multiplexing concept, we hypothesized that 2R-ohnologues that are positive effectors of an active oncogenic driver should be kept free of loss-of-function mutations in a cancer. By contrast, mutations may accumulate in sister 2R-ohnologues that are components of signalling networks that are irrelevant or inhibitory to the cancer. Finding the putative non-mutated 2R-ohnologues would need cumulative data from multiple samples, because each cancer cell lineage might have only a few of the allowed mutations spread among many 2R-ohnologue families. The recent availability of large datasets of mutations in a variety of cancer types \[[@RSOB140029C15],[@RSOB140029C25]\] therefore provided the first opportunity to explore this hypothesis. We reveal striking hierarchical patterns in the distributions of mutations within 2R-ohnologue families in cancers. Our findings support the concept of selected 2R-ohnologues being maintained free of mutations as 'effectors' in certain cancers.

3.. Results {#s2}
===========

3.1.. 2R-ohnologues carry a higher relative mutation load than non-ohnologues in every cancer type examined {#s2a}
-----------------------------------------------------------------------------------------------------------

Alexandrov *et al*. \[[@RSOB140029C15]\] validated almost 5 million somatic mutations identified in the genome sequences of 7042 samples from 30 different cancer types, but not in matched DNA from normal cells. We used the Alexandrov data to examine the distribution of mutations in 2R-ohnologue versus non-ohnologue genes (electronic supplementary material, table S1). A striking imbalance was revealed ([figure 1](#RSOB140029F1){ref-type="fig"}). Although 2R-ohnologues comprise only approximately 30% of protein-coding genes in the human genome ([figure 1](#RSOB140029F1){ref-type="fig"}*a*), they carry a higher proportion of the somatic mutations in transcript-coding genes in every cancer examined ([figure 1](#RSOB140029F1){ref-type="fig"}*b*; statistics in the electronic supplementary material, figure S1). The proportions range from 42% of gene mutations located in 2R-ohnologues in kidney clear cell carcinoma to 60% in liver cancer and in B-cell lymphoma. The greater prevalence of mutations among 2R-ohnologues is not due to differences in gene sizes: 2R-ohnologue genes average 2400 nucleotides in length and non-ohnologues 2200 nucleotides (electronic supplementary material, figure S2). Figure 1.Distributions of cancer mutations between 2R-ohnologue and non-ohnologue transcript-coding genes in 30 different cancers. (*a*) The bar shows the percentage of 2R-ohnologue and non-ohnologue transcript-coding genes in the Ensembl 72 dataset, based on the provisional 2R-ohnologue list compiled by Makino & McLysaght \[[@RSOB140029C10]\]. Note that assignment of which human genes are 2R-ohnologues is still undergoing revision. (*b*) For each cancer type analysed \[[@RSOB140029C15]\], the graph on the left side reports the percentage of mutations that map on 2R-ohnologue and non-ohnologue genes. The right side reports the log~10~ value of the total number of mutations identified in each cancer type in this dataset.

3.2.. Identification of 2R-ohnologue families in which one gene carries most of the mutations {#s2b}
---------------------------------------------------------------------------------------------

We next investigated how the somatic mutations are distributed among members of each 2R-ohnologue family, analysing each cancer type separately. To this aim, each 2R-ohnologue gene was given a mutation load (ML) score (electronic supplementary material, table S2). A gene that accumulates most of the mutations for its 2R-ohnologue family scores close to 1, while genes that are clear of mutations relative to their sister genes score close to 0. Repeats of mutations at the same position were scored as a single mutation because we did not wish to rediscover, nor have the analysis dominated by, recurrent driver mutations. Also, we included only families for which at least one gene carried 10 or more different mutations in the cancer type. This method therefore captured genes with broad patterns of mutations at multiple positions.

The ML distributions for the melanoma dataset are graphed in [figure 2](#RSOB140029F2){ref-type="fig"}*a* and for other cancers in the electronic supplementary material, data file S1 (with statistical note in legend). In melanoma and other tumour types, there were 2R-ohnologue families in which the MLs were evenly distributed among family members, such as the HECW family of two E3 ubiquitin ligases ([figure 2](#RSOB140029F2){ref-type="fig"}*b*). However, in most cancers, including melanoma, there were also 2R-ohnologue families with a 'skewed ML', meaning that one gene carried most of the ML. For example, in the melanoma dataset PAK7 carries 95 of the 114 mutated sites in the family of three type II PAK protein kinases ([figure 2](#RSOB140029F2){ref-type="fig"}*b*). Figure 2.MLs of 2R-ohnologue genes in melanoma. (*a*) For the melanoma dataset \[[@RSOB140029C15]\], the figure plots the ML distribution for 2R-ohnologues within families of 2, 3 and 4 members. Only families in which at least one gene carries carried 10 or more different mutations are included. The ML is computed by summing the total number of mutations identified for a gene divided by the total number of mutations in all members of the same 2R-ohnologue family. The *y*-axes give the number of genes, with the ML scores indicated on the *x*-axes. Each histogram set indicates the medians (red lines), interquartile ranges (rectangular boxes) and outliers (green diamonds) for the ML distributions. Note that for families of 2 members, the median will always be 0.5 by construction, regardless of the ML distribution profile. Data file S1 in the electronic supplementary material presents the corresponding histograms for 30 cancer types, and its legend contains a discussion note about statistics. (*b*) The distribution of mutations in melanoma is given for the HECW E3 ubiquitin ligase family (as an example of even ML distribution) and the type II PAK family (an example with a skewed ML where the PAK7 gene accumulates most of the family mutations). Illustrations were created with D[omain]{.smallcaps} G[raph]{.smallcaps}, v. 1.0.5 \[[@RSOB140029C26]\]. CDS is coding sequence, UTR refers to 3′ and 5′ UTRs, and mutations are indicated by vertical black lines. Data file S2 in the electronic supplementary material gives similar diagrams for the distributions of mutations in other 2R-ohnologue families in melanoma.

By contrast, there were no 2R-ohnologue families with skewed MLs in cervical, thyroid, myeloma and kidney papillary cancers (electronic supplementary material, tables S1 and S2). This was likely to be due to insufficient data for these cancer types; there were 10 or more mutations in only 23 2R-ohnologue genes in the cervical cancer samples, seven in thyroid, one in myeloma and nine in kidney papillary cancer samples. This may also be indicative of particular tumourigenesis mechanisms acting in these cancers.

3.3.. In 315 2R-ohnologue families, the same gene carries the highest mutation load in multiple cancers {#s2c}
-------------------------------------------------------------------------------------------------------

A total of 673 2R-ohnologue families displayed highly skewed MLs in one or more cancers (electronic supplementary material, table S3). This dataset was visualized in a VisANT network graph in which each cancer type is assigned a hexagonal blue node, connected to circular nodes (green, red or orange) that each represent a 2R-ohnologue family with a skewed ML in that cancer ([figure 3](#RSOB140029F3){ref-type="fig"}). The 'elegant relaxing' VisANT rule was applied \[[@RSOB140029C27]\], which means that 2R-ohnologue families with a skewed ML in only one cancer fan to the outside of the graph, while those with a skewed ML in multiple cancers are pulled towards the centre ([figure 3](#RSOB140029F3){ref-type="fig"}). The layout of the graph therefore reflects patterns in the data. Figure 3.VisANT map of 2R-ohnologue families that display skewed MLs in different cancer types; graph created using VisANT ([visant.bu.edu](visant.bu.edu) \[[@RSOB140029C27]\]) from the data in the electronic supplementary material, table S3. Each cancer was assigned a node in blue and lines connect these cancers to the 2R-ohnologue families (in green, red or orange) that display a skewed ML in that cancer. For a line to join a cancer and a 2R-ohnologue family, at least one gene in the family had to carry at least 10 different mutations in that cancer. Also, we plotted only those families with ML skew above the thresholds of at least 0.9 for families containing two genes (that is one gene carried more than or equal to 90% of the mutated positions for its family), at least 0.8 for families with three genes and at least 0.7 for families of four genes. The red node labelled 'P53-F' is the p53/p63/p73 family, and the orange node marked 'FOG-F' represents FOG1/FOG2.

Cancers around the top and sides of the graph, namely melanoma, breast, lung adenocarcinoma, liver, pancreatic, B-cell lymphoma and chronic lymphocytic leukaemia (CLL), are characterized by relatively high numbers of ML-skewed families ([figure 3](#RSOB140029F3){ref-type="fig"}). Each of these cancers has 2R-ohnologue families for which ML skews were identified only in the individual cancer, which may be 'signatures' reflecting the tissues of origin of these cancers. However, these cancers are also highly interlinked by the many other ML-skewed 2R-ohnologue families that they have in common. Paediatric medulloblastoma is also highly interlinked, being central on the graph because it shares 120 ML-skewed families with other cancers, while only 20 ML-skewed families are unique to medulloblastoma ([figure 3](#RSOB140029F3){ref-type="fig"}; electronic supplementary material, table S3).

Overall, 322 2R-ohnologue families displayed a ML skew in two or more cancers (electronic supplementary material, table S3). Remarkably, in 315 of these 322 families, the same gene carried the highest ML in each of the linked cancer types ([figure 3](#RSOB140029F3){ref-type="fig"}; electronic supplementary material, table S3 with statistical note in legend, and data file S2). Furthermore, in most of these 322 families, the same gene carried the second highest ML for each family in each of the linked cancer types ([table 1](#RSOB140029TB1){ref-type="table"}; electronic supplementary material, table S3, and statistical note in legend). For example, in the cumulative data for nine cancer types, the protein receptor tyrosine phosphatase PTPRD has many more mutated sites than PTPRS, while PTPRF is rarely mutated; in seven cancers, the Discs large homologue DLG2 is by far the most often mutated, DLG1 second, and DLG3 and DLG4 rarely mutated; the EGF receptor family member ERBB4 carries far more mutations than EGFR, while ERBB2 (HER2) and ERBB3 have relatively few nucleotides mutated in seven cancers ([table 1](#RSOB140029TB1){ref-type="table"}; electronic supplementary material, table S3). Thus, the relative MLs in such 2R-ohnologue families are under selection pressures that act in a quantitative manner. Table 1.Rank orders of ML scores within ML-skewed families. Electronic supplementary material, table S3, and [figure 3](#RSOB140029F3){ref-type="fig"} contain data for all the 2R-ohnologue families that have extreme ML skews. This table shows only those families of three and four members with high ML skews in at least four cancers. The table shows which 2R-ohnologues carry the highest number and second highest number of different mutations for its family. The last column indicates how many cancers have that same rank order of MLs for each family. The ML scores for the 2R-ohnologue families of two members can be viewed in the electronic supplementary material, table S3. The family identifier is an arbitrary number assigned to each 2R-ohnologue family in \[[@RSOB140029C7]\].2R-ohnologue family identifier number and family descriptionmost mutated member of the 2R-ohnologue familysecond most mutated family memberleast mutated family member(s)no. cancers where the proteins indicated to the left are ranked first and second most mutated in the family60P53 tumour suppressor familyP53P63P7313 of 14177cyclic nucleotide-gated ion channelsHCN1HCN4HCN2, HCN310 of 10309receptor tyr phosphatasesPTPRDPTPRSPTPRFnine of nine904low-density lipoprotein receptorsLRP1BLRP2LRP1nine of nine724N-acetylglucosaminyltransferasesMGT4CMGT4AMGT4Beight of eight1621bHLH transcription factorsNPAS3SIM1NPAS1, SIM2seven of eight66Ca^2+^-binding cadherin-likeCSTN2CSTN1CSTN3seven of seven170very long chain acyl-CoA synthetasesS27A6S27A2, S27A3seven of seven for first; others equal219phosphatidylserine receptorsBAI3BAI1BAI2seven of seven289RNA-binding proteinsRALYLRALYHNRPC, HNRCLseven of seven689Kv channel-interacting proteinsKCIP4KCIP1CSEN, KCIP2seven of seven785EGF receptor familyERBB4EGFRERBB2, ERBB3seven of seven1117Discs large homologuesDLG2DLG1DLG3, DLG4seven of seven1547transmembrane proteinsTM14BTM14CTM14Aseven of seven for first; five of seven for second1706autism susceptibilityAUTS2FBSLFBRSsix of seven1727engulfment and cell motility proteinsELMO1ELMO2ELMO3seven of seven for first; six of seven for second61Kv channel subunitsKCAB1KCAB2KCAB3six of six89synaptophysin-like proteinsSYNPRSYPL1, SYPL2, SYPHsix of six for first, others equal157leucine-rich repeat proteinsLRRC7LAP2SCRIB, LRRC1six of six for first, five of six for second246choline transporter-likeCTL5CTL2CTL4six of six for first, five of six for second277Kv channel subunitsKCND2KCND3KCND1six of six482liprin familyLIPA2LIPA1LIPA3, LIPA4six of six725guanine exchange factors for ARF GTPasesPSD3PSD2PSD1, PSD4six of six for first, three of six for second948protein kinase D familyKPCD1KPCD3KPCD2six of six1327Dickkopf-related, Wnt antagonistsDKK2DKK4, DKK1six of six for first, others equal2105C2-containing calcium sensorsRP3ADOC2ADOC2Bsix of six2215type II cdc42-interacting protein kinasesPAK7PAK4, PAK6six of six for first, others equal2275RNA-binding splicing regulatorsRFOX1RFOX3RFOX2six of six for first, five of six for second28zinc transportersZNT8ZNT4ZNT2, ZNT3five of five for first, four of five for second47histone lysine N-methyltransferasesSMYD3SMYD1SMYD2five of five for first, three of five for second139PI 3-kinase regulatory subunitsP85AP85BP55Gfive of five for first, four of five for second287muscarinic acetylcholine receptorsACM2ACM3ACM1, ACM5four of five for first, four of five for second479a synaptotagmin familySYT1SYT2SYT5five of five515hypoxia-inducible prolyl hydroxylasesEGLN3EGLN1EGLN2five of five525protein kinase B familyAKT3AKT2AKT1five of five for first, four of five for second649single-stranded DNA/RNA interactingRBMS3RBMS1RBMS2five of five806type II histone deacetylasesHDAC9HDAC4HDAC5, HDAC7five of five872integrin alpha familyITA8ITAVITA2B, ITA5five of five for first, four of five for second882accessory to TGFbeta assemblyLTBP1LTBP2LTBP3, LTBP4five of five941serotonin receptors5HT2C5HT2A5HT2Bfive of five1085diacylglycerol kinasesDGKBDGKGDGKAfive of five1443zinc-finger DNA-binding proteinsZMAT4ZMAT1ZN346five of five for first, three of five for second1996localization of receptors and ion channelsLIN7ALIN7CLIN7Bfour of four for first, three of four for second106voltage-gated calcium channel subunitsCAC1CCAC1DCAC1S, CAC1Ffour of four140Rab3 GTPase in exocytotic vesicle fusionRAB3CRAB3BRAB3D, RAB3Afour of four for first, three of four for second193transcription factorsRUNX1RUNX2RUNX3four of four196regulator in Ras signalling pathwayCNKR2CNKR3CNKR1four of four for first, three of four for second254deubiquitylating enzymesOTU7AOTU7BTNAP3four of four386dynamin vesicle trafficking proteinsDYN3DYN1, DYN2four of four for first, others equal541RNA-splicing proteinCELF4CELF5CELF3, CELF6four of four for first, three of four for second632poly(rC)-binding proteinsPCBP3PCBP2PCBP1, PCBP4four of four915RNA-binding zinc-finger proteinsZ385DZ385BZ385Afour of four1103cell adhesion moleculesCD166MUC18BCAMfour of four for first, two of four for second1909exocytosis, regulated by diacylglycerolUN13CUN13BUN13Afour of four for first, two of four for second2301vesicle regulators alcohol dehydrogenase familyVAT1LZADH2VAT1four of four2377histone demethylasesKDM6AUTYKDM6Bfour of four for first, three of four for second

We checked whether any of the genes with low ML scores in these 322 families had recurrent mutations in the same position, indicative of potential drivers. However, there were few repeated mutations in these low-ML genes.

3.4.. A distinct group of cancers in which p53 is the most mutated member of the p53/63/73 family has low connectivity to other mutation load-skewed families {#s2d}
-------------------------------------------------------------------------------------------------------------------------------------------------------------

The ML skew characteristics of cancers in different regions of [figure 3](#RSOB140029F3){ref-type="fig"} are summarized in [table 2](#RSOB140029TB2){ref-type="table"}. Interestingly, a distinct cluster of cancers at the bottom of the graph is characterized by a high ML skew in the p53/63/73 family (red node on [figure 3](#RSOB140029F3){ref-type="fig"}). Green nodes are relatively sparse in this region of the graph, meaning that these cancers have ML skews in relatively few other 2R-ohnologue families. Furthermore, the ML-skewed families associated with this cancer cluster are generally not shared by cancers in the upper region of the graph. Table 2.Characteristics of cancers in different regions of the VisANT graph in [figure 3](#RSOB140029F3){ref-type="fig"}. In this table, cancers are loosely clustered according to the indicated characteristics. The data for mutations in p53, p63 and p73 for all cancers (from electronic supplementary material, table S2) are summarized in the electronic supplementary material, figure S5. Note that for all cancers with at least 10 mutations in at least one member of the p53/p63/p73 family, p73 always carries the lowest number of mutations in this dataset (electronic supplementary material, figure S3).position on graph in [figure 3](#RSOB140029F3){ref-type="fig"}cancers in clusterconnected to ML-skewed familiesabove-threshold ML skew within p53/63/73 family?top and sidesmelanoma, B-cell lymphoma, breast, CLL, liver, lung adenocarcinoma, pancreatic, stomach, uterushighly connected. Each cancer has both unique and shared ML-skewed familiesno: melanoma, liver and B-cell lymphoma have most mutations in p63, while the other cancers have p53 as the most mutated protein, but these trends are below the skew thresholds for these cancers to be linked to the p53/p63/p73 in [figure 3](#RSOB140029F3){ref-type="fig"}centremedulloblastomahighly connected, with 120 ML-skewed families shared with other cancers and 20 ML-skewed families unique to medulloblastomayes: p63 is the most mutated member of this familybottomALL, AML, bladder, colorectal, esophageal, glioblastoma, glioma (low grade), head-and-neck, lung squamous, ovary, prostate, kidney chromophoberelatively few ML-skewed families are linked to each cancer in this clusteryes: p53 is the most mutated member of this familyunconnectedcervical, kidney papillary, kidney clear cell carcinoma, myeloma, thyroidunconnected to any ML-skewed familiesno: cancers have fewer than nine mutations in p53/p63/p73 family in this datasetneuroblastomaonly one ML-skewed family, namely ALK/LTK (ALK most mutated, including well-known mutations)no: only one p53 mutation and two p63 mutations in datasetpilocytic astrocytomaconnected to only three ML-skewed families, two of which are also highly connected to other cancers (LRP1B-most mutated, PTPRD-most mutated), the third being the Raf family (B-Raf most mutated)no: only two mutations in the p53/p63/p73 family in dataset; one in p63 and one in p73

The p53 gene has a higher ML than p63 and p73 in most of the cancers in this lower cluster, namely acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL), bladder, colorectal, esophageal, glioblastoma, low-grade glioma, head-and-neck, chromophobe renal cell carcinoma, small cell lung carcinoma and lung squamous cancers (electronic supplementary material, figure S3; [figure 3](#RSOB140029F3){ref-type="fig"}). However, the p53/63/73 family was one of only seven 2R-ohnologue families whose ML skew switched according to cancer type, and p63 has a far higher ML than p53 and p73 in medulloblastoma (electronic supplementary material, table S3 and figure S3). Medulloblastoma has a low incidence of p53 mutations associated with poor prognosis in subtypes with activated Wnt signalling and polyploid cases with activated hedgehog signalling, but p53 mutations are generally not in Group 3 and 4 subtypes \[[@RSOB140029C28]--[@RSOB140029C30]\]. However, p63 mutations were found in every medulloblastoma subtype (electronic supplementary material, table S4).

Cancers in the upper region of [figure 3](#RSOB140029F3){ref-type="fig"}, such as melanoma, breast and liver cancer, are not linked to the p53/63/73 family node because, while these cancers can carry various mutations in p53 and p63, they do not display a strong ML skew in this gene family ([table 2](#RSOB140029TB2){ref-type="table"}; electronic supplementary material, figure S3).

3.5.. The p53/63/73 and FOG1/2 mutation load-skewed families together link to 22 of the 30 cancers examined {#s2e}
-----------------------------------------------------------------------------------------------------------

The p53/63/73 family has an ML skew in 14 cancer types (red nodes in figures [3](#RSOB140029F3){ref-type="fig"} and [4](#RSOB140029F4){ref-type="fig"}*a*). Also linked to many cancers is the FOG1/2 (Friend of GATA 1/2) family in which FOG2 is more commonly mutated than FOG1 (orange node on figures [3](#RSOB140029F3){ref-type="fig"} and [4](#RSOB140029F4){ref-type="fig"}*a*; electronic supplementary material, table S3). Between them, the p53/63/73 and FOG1/2 ML-skewed families link to 22 of the 30 cancers examined, with an overlap of only three cancer types ([figure 4](#RSOB140029F4){ref-type="fig"}*a*). Other 2R-ohnologue families displaying high ML skews in 10 or more cancers are those with the following proteins most mutated: potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1), tectorin alpha (TECTA), receptor-type tyrosine-protein phosphatase delta (PTPRD), low-density lipoprotein receptor-related protein 1B (LRP1B), MAM domain-containing glycosylphosphatidylinositol anchor protein 2 (MDGA2) and protein phosphatase 1 regulatory subunit 9A (neurabin-1) (electronic supplementary material, table S3). Figure 4.Associations between specific cancers and specific mutation-load-skewed 2R-ohnologue families. (*a*) Data extracted from [figure 3](#RSOB140029F3){ref-type="fig"}, showing the cancers for which there are ML skews in the p53/p63/p73 and FOG1/FOG2 protein families. (*b*) A graph showing those 2R-ohnologue families that display a skewed ML in the cumulative data from those melanoma and colorectal cancer samples that have either a B-Raf^V600E^ or N-Ras^Q61K/R^ mutation (data in the electronic supplementary material, table S5). 'Common' indicates 2R-ohnologue families that have a skewed ML in the data from both the B-Raf^V600E^-mutated and the N-Ras^Q61K/R^-mutated samples.

3.6.. 2R-ohnologue families with skewed mutation loads in cancer samples that carry activating driver mutations in B-Raf and N-Ras {#s2f}
----------------------------------------------------------------------------------------------------------------------------------

We hypothesized that cancers with drivers that activate different signalling pathways may depend on different subsets of non-mutated 2R-ohnologue effectors. Therefore, from the 7042 samples in the dataset \[[@RSOB140029C15]\], we selected those with activating mutations in either B-Raf or N-Ras (electronic supplementary material, table S5). Generally, these two mutations are mutually exclusive. A subset of skewed-ML families co-occurred with either B-Raf^V600E^ or N-Ras^Q61K/R^ in melanoma ([figure 4](#RSOB140029F4){ref-type="fig"}*b*). Of these, a smaller subset of families had ML skews in both the Raf- and Ras-mutated melanoma samples; these included the type II PAK kinases (PAK7 most mutated) and FOG1/2 family (FOG2 most mutated) ([figure 4](#RSOB140029F4){ref-type="fig"}*b*; electronic supplementary material, table S5).

By contrast, in colorectal cancer the p53 family was one of seven families whose ML skew (p53 most mutated) coincided with B-Raf^V600E^ mutations, while the adenomatous polyposis coli family (APC more mutated than APC2) had ML skews in colorectal cancers with either B-Raf^V600E^ or N-Ras^Q61K/R^ ([figure 4](#RSOB140029F4){ref-type="fig"}*b*). Thus, our unbiased analysis rediscovered the well-known dominance of APC driver mutations in these tumours, which can also acquire Ras and p53 driver mutations as they progress \[[@RSOB140029C31]\]. We note that as well as the V600E driver mutation, B-Raf acquired 107 different mutations in the colorectal cancer samples (electronic supplementary material, table S3). Finding that many different B-Raf mutations are allowed to occur in colorectal cancer (as well as the fact that APC mutation dominates) is consistent with findings that B-Raf^V600E^ inhibitors are generally not therapeutically useful in this tumour type \[[@RSOB140029C31]--[@RSOB140029C33]\].

3.7.. The relative mutation load of a 2R-ohnologue is moderately predictive of its altered mRNA expression in melanoma {#s2g}
----------------------------------------------------------------------------------------------------------------------

An important question is whether the 2R-ohnologues that are relatively free of mutations are expressed in the cancers. While we cannot answer this question for the Alexandrov *et al.* \[[@RSOB140029C15]\] dataset, other available data record differences in mRNA levels between samples of malignant cancers compared with benign or normal controls. We found a moderate, but statistically significant tendency for 2R-ohnologues with low ML scores (mutation-free relative to sister 2R-ohnologues) to have their mRNA levels strongly upregulated in melanoma in the E-GEOD-3189 dataset \[[@RSOB140029C34]\] ([figure 5](#RSOB140029F5){ref-type="fig"}; electronic supplementary material, figure S4 and table S6). A similar trend was observed in the E-GEOD-32867 dataset, which reports gene expression levels in lung adenocarcinoma relative to adjacent non-tumour tissue (electronic supplementary material, figure S5 and table S7). These results indicate the existence of selection pressures that affect the expression levels of certain 2R-ohnologues in cancer cells. The 2R-ohnologues whose expression is altered in the cancer have a greater tendency to be maintained with a low ML. Figure 5.Relationships among ML of 2R-ohnologues in melanoma, cancer/control mRNA expression in melanoma and proteins identified in 14-3-3-affinity capture experiments using melanoma cell lysates. Each cross represents a gene in the E-GEOD-3189 transcription profiling dataset \[[@RSOB140029C34]\]. The log~2~ ratio of mRNA expression in malignant melanoma versus benign melanocytic lesions in the E-GEOD-3189 dataset is plotted on the *y*-axis against the ML score of the gene calculated from the Alexandrov *et al.* \[[@RSOB140029C15]\] data on the *x*-axis. The genes whose mRNA levels are most strongly up- or downregulated in melanoma are in red and blue, respectively. Also plotted (circles) are the proteins that were isolated by 14-3-3-affinity capture of cell lysates from both SKMEL13 and SBCL2 melanoma cells, and identified by mass spectrometric analyses. The data used for this figure are in the electronic supplementary material, table S6.

3.8.. 2R-ohnologues with low mutation loads can be isolated by 14-3-3-affinity capture from lysates of melanoma cells {#s2h}
---------------------------------------------------------------------------------------------------------------------

We also wished to assess whether 2R-ohnologues with low MLs are expressed as proteins in the relevant cancers. To this end, we took advantage of the fact that Ras--Raf and certain other oncogenic signalling pathways stimulate the phosphorylation of many proteins that consequently dock onto the phosphoprotein-binding 14-3-3 proteins \[[@RSOB140029C35]--[@RSOB140029C37]\]. Moreover, the 14-3-3-binding phosphoproteome is enriched in 2R-ohnologues \[[@RSOB140029C7],[@RSOB140029C38]--[@RSOB140029C41]\].

14-3-3-affinity capture was therefore used to isolate (phospho)proteins from lysates of SKMEL13 melanoma cells that carry B-Raf^V600E^ and also SBCL2 N-Ras^Q61K^ melanoma cells (electronic supplementary material, figure S6, and tables S8 and S9). Of the 1007 proteins that were 14-3-3-affinity captured and identified in a total of two experiments from both cell lysates, 68 were previously reported 14-3-3-binding phosphoproteins (gold standards), and 480 proteins were 2R-ohnologues. Of these, 62 had ML scores of less than 0.2 in the melanoma dataset of 2R families in which at least one member had 10 or more mutations (electronic supplementary material, table S10). These results indicate that at least some 2R-ohnologues with low ML scores are expressed as proteins in relevant cancer cells.

Further analysis identified candidate 'lynchpin' 14-3-3-binding phosphosites in 286 of the melanoma 14-3-3-affinity captured 2R-ohnologues \[[@RSOB140029C42]\]. Lynchpins are 14-3-3-binding phosphosites whose positions are conserved across members of a given 2R-ohnologue family \[[@RSOB140029C7]\]. From the overall analysis, we assembled a stringent list of 235 known and candidate 14-3-3 binding partners (electronic supplementary material, table S10). Interestingly, 143 proteins from this stringent list could be mapped to the E-GEOD-3189 melanoma transcriptome dataset and were moderately overrepresented among 2R-ohnologues with low ML scores ([figure 5](#RSOB140029F5){ref-type="fig"}). Specifically, 111 of these 143 (78%) 14-3-3-affinity captured proteins were among the 66% of this dataset that had ML scores of less than 0.5 (electronic supplementary material, table S6). In summary, these pilot experiments indicate the potential of 14-3-3-affinity capture for isolating 2R-ohnologue proteins to dissect their biochemical regulation in cancers.

3.9.. Overexpression of protein kinase 2R-ohnologues with low mutation load scores decreased the sensitivity of B-Raf^V600E^-mutant melanoma cells to PLX4720 {#s2i}
-------------------------------------------------------------------------------------------------------------------------------------------------------------

One further observation is consistent with the notion that 2R-ohnologues with low ML scores are functionally relevant for cancer: Wood *et al.* \[[@RSOB140029C43]\] screened for protein kinases whose overexpression rendered B-Raf^V600E^-melanoma cells resistant to the B-Raf^V600E^ inhibitor, PLX4720. We noted that 2R-ohnologue protein kinases with low ML scores in melanoma (this study) tended to be better at rendering cells resistant to PLX4720 \[[@RSOB140029C43]\], compared with their sisters that have high ML scores ([table 3](#RSOB140029TB3){ref-type="table"}). The trend of 'highest viability score = lowest ML score' was observed even within protein kinase families that display moderate ML skews in melanoma ([table 3](#RSOB140029TB3){ref-type="table"}). This finding suggests that the protein kinases with low ML scores may contribute to melanoma progression by a mechanism that is linked to B-Raf^V600E^. Table 3.Overexpression of protein kinase 2R-ohnologues with low mutation scores decreased the sensitivity of B-Raf^V600E^-mutant melanoma cells to PLX4720. The viability score assigned by Wood *et al.* \[[@RSOB140029C43]\] refers to the ability of the protein kinase, when overexpressed, to enhance the viability of B-Raf^V600E^-mutant melanoma (A375) cells exposed to the B-Raf^V600E^ inhibitor, PLX4720. Seven 2R-ohnologue families of protein kinases had least one member among the top hits of the Wood dataset \[[@RSOB140029C43]\] and at least one member with at least 10 mutations in melanoma in the Alexandrov dataset \[[@RSOB140029C15]\]. The cell viability scores \[[@RSOB140029C42]\] and ML scores (this study) are shown for each member of these seven families. The family Id is an arbitrary number assigned to identify each 2R-ohnologue family in \[[@RSOB140029C7]\]. n.a., data not available.2R-ohnologue family Idprotein nameUniProt Idviability score \[[@RSOB140029C42]\]ML score in melanoma (electronic supplementary material, table S2)is ML skew in melanoma above threshold for inclusion in [figure 3](#RSOB140029F3){ref-type="fig"} and the electronic supplementary material, table S3?378NTRK2Q166201.230.0777no378NTRK1P046291.070.3932no378NTRK3Q16288n.a.0.2621no378MUSKO151460.760.2670no1058MST1RQ049121.130.2923no1058METP085811.030.7077no1085MAPK8P459831.180.1563no1085MAPK9P459840.930.3438no1085MAPK10P537790.790.5000no1548SRPK3Q9UPE11.160.2195no1548SRPK1Q96SB40.950.3415no1548SRPK2P783620.860.4390no1666PIM2Q9P1W91.150.3182no1666PIM1P113091.110.5000no1666PIM3Q86V86n.a.0.1818no1780LIMK1P536671.170.3103no1780LIMK2P536710.940.6897no2215PAK6Q9NQU51.210.0877yes2215PAK4O960130.970.0789yes2215PAK7Q9P2860.860.8333yes

4.. Discussion {#s3}
==============

Here, knowledge of the evolutionary history of the human genome was used to unlock patterns in a heterogeneous dataset of somatic mutations from many cancers. Our findings cannot be accommodated within the conventional binary driver/passenger model \[[@RSOB140029C16],[@RSOB140029C32]\].

In every cancer type examined, somatic mutations are more prevalent in 2R-ohnologues than in non-ohnologue genes. Because 2R-ohnologues are enriched in signalling proteins \[[@RSOB140029C6],[@RSOB140029C7]\], this finding is consistent with cancer being a disease in which regulatory processes go awry.

A second finding was that in a subset of cancers---particularly melanoma, lung adenocarcinoma, breast and liver cancers, B-cell lymphoma and medulloblastoma---there are 2R-ohnologue families in which one gene carries multiple mutations in the cumulative data, while sister genes in the same family are relatively mutation-free. Most notably, in 315 out of the 322 2R-ohnologue families displaying a high skew in multiple cancers the *same gene* carries the heaviest ML in each cancer, and for families of more than two members, usually the second-ranked gene is also the same in each cancer.

Generally, each gene in a 2R-ohnologue family is on a different chromosome, and the non-mutated 2R genes in the ML-skewed families are widely distributed in the genome. It therefore seems unlikely that all of these are in genomic regions that are protected from mutation, though this possibility must be formally tested.

Rather, we favour a conceptually simple working model ([figure 6](#RSOB140029F6){ref-type="fig"}). The invertebrate ancestor of the vertebrates is depicted as having cells controlled by linear regulatory pathways. Via the 2R-WGD leap, these pathways were quadruplicated, generating the complex networks that transmit multiple regulatory signals in vertebrate cells. In certain cancers such as melanoma and breast cancer, heterogeneous patterns of multiple mutations (black crosses in [figure 6](#RSOB140029F6){ref-type="fig"}) result in the shutdown of certain routes through these communication networks. Information flow is therefore forced through a limited number of 'open' network pathways, which are driven by activating oncogenic driver mutations (star symbols in [figure 6](#RSOB140029F6){ref-type="fig"}) and also depend on specific non-mutated 2R-ohnologues as effectors. Figure 6.Simplified model that depicts cancer as a disorder of signal multiplexing in the cellular 2R-WGD networks of vertebrate animals. (*a*) The ancestor of all the vertebrates was an invertebrate chordate whose cells are depicted as being under the control of simple linear regulatory pathways. The image is of amphioxus (*Branchiostoma*), regarded as the best modern-day proxy for the ancestor. (*b*) 2R-WGD at the evolutionary origins of the vertebrate animals boosted communication networks inside our cells. Variations in these networks may underpin variety of vertebrate cell types, species and behaviours. (*c*) We hypothesize that certain cancers arise when different heterogeneous combinations of mutations (crosses) disconnect certain parts of the 2R-WGD regulatory networks and force too much communication flow via a restricted number of oncogenic pathways. These 'open' oncogenic pathways are activated by specific driver mutations (stars) and also require effector proteins that must remain mutation-free. If these effectors acquire too many deleterious mutations, the cancer cell will be lost. Though the model only depicts 2R families with high ML skews, it could be extended to include other patterns. For example, 2R families whose members carry an even ML may be in parts of the network where any member can perform the family function for the cancer, or represent functions whose total elimination gives a selective advantage to the cancer. In its simple form, the model assumes that when genes are hit by a number of different mutations (crosses) these will include loss-of-function mutations. However, it is appreciated that this may not always be so, in which case the rules of the model would change. The model highlights that the contribution of both mutated and non-mutated 2R-ohnologues to the overall function of each family in the cancer should be considered.

In this model, driver mutations that activate the 'open' oncogenic pathways will be under positive selection, whereas essential effectors of these drivers will be under purifying selection to be maintained mutation-free. By contrast, 2R-ohnologues in the 'shut down' part of the signalling network will experience different selection pressures that vary with time. Our findings indicate quantitative hierarchies in how mutation burdens are distributed across 2R-ohnologue families in cancers that conform to our model. We therefore suggest that mutations that block tumour-suppressing pathways through the network will be under positive selection until these routes are closed, at which time these pathways will join the ones that are irrelevant to the cancer, where further mutations will be under neutral selection.

The heterogeneity of so-called passenger mutations is generally taken to imply that these represent clinically inconsequential 'noise'. However, in our model such heterogeneity reflects the possibility that there are multiple ways to disable parts of the 2R-WGD networks, while still leaving the oncogenic pathways open. These findings raise challenging questions of redundancy and essentiality of family members at the biochemical level. Why are certain 2R genes quantitatively more important to a cancer than their sisters? As more cancer mutation data are collected, it will be fascinating to see how the overall ML rankings resolve.

Through this study, we realize that recurrent oncogenic driver mutations, genes with multiple mutations and non-mutated genes can each occur within the same 2R-ohnologue family, or even in the same gene, in different cancer contexts. For example, neuroblastoma presented with only one ML-skewed gene family (the ALK/LTK receptor tyrosine kinases), which includes driver mutations known to activate ALK in this disease \[[@RSOB140029C44]\]. However, the cumulative data for lung adenocarcinoma, breast and liver cancers contain a few hundred different mutations in ALK, but few in its sister LTK, an imbalance that is inconsistent with ALK being an activated driver in these cancers.

An important question arising from our model is whether the mutation-free 2R-ohnologues that are putative effectors of oncogenic drivers will be good targets for therapeutic intervention. While a logical proposition, unfortunately these mutation-free genes are largely understudied. For example, there is intense focus of research on the inactivating mutations in APC in colorectal cancers \[[@RSOB140029C31]\]. However, it is conceivable that the loss of APC renders these cancers dependent on APC2, and to our knowledge this hypothesis has not been tested. Similarly, many FOG2 mutations, but few in FOG1, were found in 11 cancer types. Therefore, targeting FOG1 for inactivation seems logical. Furthermore, the FOG family (FOG2 most mutated) was among several 2R families whose skewed MLs coincided with activating B-Raf^V600E^ and N-Ras driver mutations in melanoma. Targeting aberrant Raf signalling is therapeutic in melanoma \[[@RSOB140029C31],[@RSOB140029C33]\], so it will be important to define the biochemical relationships between Ras--Raf signalling and FOG proteins in melanoma. Interestingly, FOG1 interacts with the GATA transcription factors, which include GATA2, which is essential for proliferation of cancer cells carrying oncogenic K-Ras \[[@RSOB140029C45]\]. The type II PAK kinases (PAK7 most mutated) also showed a ML skew in melanomas with B-Raf^V600E^ and N-Ras driver mutations. Furthermore, PAK4 and PAK6 have much lower MLs than PAK7 in six cancers; PAK4, PAK6 and PAK7 are 14-3-3-binding phosphoproteins \[[@RSOB140029C42],[@RSOB140029C46]\]; PAK4 was 14-3-3-affinity captured here from melanoma cell lysates; and overexpressed PAK4 and PAK6 were more effective than PAK7 in enhancing the viability of B-Raf^V600E^-mutant melanoma cells exposed to PLX4720 \[[@RSOB140029C43]\]. These findings suggest that, for unknown reasons, the PAK4/PAK6 kinases are more important than PAK7 in melanoma.

STRING analysis \[[@RSOB140029C47]\] revealed that the protein families with ML skews in multiple cancers include regulatory proteins in growth factor signalling (families whose most multiply-mutated members are ERBB4, AKT3, GSK3B, ALK, KPCD1, PAK7, KCC1D, AAKG2, KPCT, FER, PTPRD, LIPA2, PTPRR, P2R3A, P85A, P3C2G, INP4B, PPM1H, IRS1, GRB2, RHEB, OTU7A), chromatin function (FOG2, RUNX1, ANM8, TREF1, SMYD3, HDAC9), membrane and cytoskeletal dynamics (UN13C, ELMO1, RAB3C, RB11A, TSNA1, RBG1L, MTUS2, RASF9, GAS2, RHG06, RRAS2, EXT1, SYT1), neurotransmission (AUTS2, DLG2, AMMR1, HIP1, CBLN2, NPAS3, CABP8, BAI3, DAB1, SYNPR, DCC, 5HT2C, LIN7A, CRUM1, ACM3, neurabin-1), ion channels (HCN1, KCIP4, KCAB1, KCND2), protein glycosylation (XYLT1, MDGA2, MGT4C, LARGE), extracellular matrix (TECTA, FREM2), angiogenesis and responses to hypoxia (BAI3, EDIL3, EGLN3). While the most mutated family members are listed here for linguistic ease, we propose the least-mutated members for attention as potential therapeutic targets. Many of these protein families have known functional links with cancer and metastases, but this dataset is also rich in ion channels and neurotransmitter systems; this is intriguing, since most of the analysed cancers are not in excitable nervous tissues. Interestingly, tumours exhibit bioelectric changes and ion channel modulation is being explored for cancer therapy \[[@RSOB140029C48],[@RSOB140029C49]\].

A distinct subset of cancers (ALL, AML, bladder, colorectal, glioblastoma, glioma, head-and-neck, ovary, kidney chromophobe) was characterized by an ML skew towards mutations in p53, and not p63 or p73. These cancers have relatively few other 2R-ohnologue families with high ML skews, and the ones that they did have generally differed from the ML-skewed families in breast, melanoma, lung adenocarcinoma and liver cancers. These 'p53-mutated, but not p63/p73-mutated' cancers may therefore require a tailored version of the model ([figure 6](#RSOB140029F6){ref-type="fig"}) to be developed.

Finally, it has been considered paradoxical that 'dangerous' cancer genes from the 2R-WGD were selectively retained during vertebrate evolution \[[@RSOB140029C11]\]. An alternative view is that the robustness of 2R-ohnologue signal-multiplexing networks enables vertebrates to survive long enough to develop cancer. Mutating one 2R-ohnologue may not be lethal if other members of the family can at least partially compensate. However, if such mutations disconnect that protein family from certain signalling networks, cells will get stuck in one signalling mode, generating the cancer phenotype. It is fascinating to discover how an ancient evolutionary leap left its mark on the genomes of vertebrate animals, on signalling complexity and on the diseases of modern humans.

5.. Material and methods {#s4}
========================

5.1.. Mapping mutations to genes and computing mutation load scores of 2R-ohnologues {#s4a}
------------------------------------------------------------------------------------

The chromosomal locations of single and double nucleotide substitutions, small insertions and deletions within the Alexandrov *et al.* \[[@RSOB140029C15]\] dataset were mapped onto nucleotide positions within protein-coding and pseudogene-RNA genes in the Ensembl 72 dataset. Briefly, the BioMart service of Ensembl ([www.ensembl.org](www.ensembl.org)) was used to retrieve the gene positions, and a Python script was compiled to identify the mutations that map within a given gene. Mutations involving more than one nucleotide were mapped to the first nucleotide change. Each mutation that maps onto the same starting nucleotide was considered only once. For example, for the B-Raf gene, the V600L and V600K amino acid substitutions start on the same nucleotide (1798G \> C and 1798_1799GT \> AA, respectively) and would count as one, whereas the V600E substitution starts one base after (1799T \> A) and would be counted separately. Gene copy number changes and changes involving more than one gene were not considered. Genes annotated as pseudogenes were included in our analysis, because functions have been identified for many such genes.

The ML for each gene was computed by summing the total number of different mutations identified for a gene (PROT ML) divided by the sum of all mutations identified in the 2R-ohnologue family components of the gene under analysis. This number scores from 1 to 0 and identifies the genes in any 2R-ohnologue family that are prone to accumulate mutations (score close to 1) or are clear of mutations (score close to 0).

The genomic nucleotide positions of mutations were translated with a Python script into the transcript nucleotide position of a protein-coding gene for making pictures of the MLs of the different family members. The BioMart service of Ensembl was used to retrieve the transcript genomic coordinates, and the longest transcript for each gene was used for this analysis.

5.2.. Lack of mutations: biological reality or missing data? {#s4b}
------------------------------------------------------------

The mutation data were derived from 507 whole genome and 6535 exome sequencing studies, and further sequencing validation experiments performed by Alexandrov *et al.* \[[@RSOB140029C15]\], the Cancer Genome Atlas, International Cancer Genome Consortium and other laboratories \[[@RSOB140029C15]\]. For our study, it was critical that genes that record few mutations represent biological reality and not false negatives due to lack of sequence coverage. There is unevenness in the dataset because, while the exome enrichment platforms that were used (Agilent, Nimblegen and Illumina) capture mainly protein-coding regions of genes, the Illumina platform gives reads in 3′ and 5′ untranslated regions (UTRs) \[[@RSOB140029C50]\] ([figure 2](#RSOB140029F2){ref-type="fig"}*b*; electronic supplementary material, data file S2). However, we did not exclude UTRs from our analysis, after checking that this would not have a general effect on which 2R-ohnologue families were designated to display an ML skew. Each exome sequencing platform misses certain 'difficult' regions \[[@RSOB140029C50]\]. However, with the possible exception of pseudogenes, the raw data in the primary studies cited in \[[@RSOB140029C15]\] give no indication of technical biases that would result in specific genes being systematically missed in the cumulative data.

5.3.. Melanoma cell culture, 14-3-3-affinity chromatography and mass spectrometric identification of proteins {#s4c}
-------------------------------------------------------------------------------------------------------------

SKMEL13 (B-RAF^V600E^) and Sbcl2 (N-RAS^Q61K^) melanoma cells were cultured in RPMI and Dulbecco\'s modified eagle medium, respectively. Media were supplemented with 10% (v/v) fetal calf serum (Thermo Scientific), 2 mM [l]{.smallcaps}-glutamine, 50 units ml^−1^ penicillin G and 50 μg ml^−1^ streptomycin (Life Technologies), and cells cultured under 5% CO~2~ at 37°C. Lysates were prepared as in \[[@RSOB140029C51]\] and subject to 14-3-3-affinity chromatography. Briefly, proteins were bound to 14-3-3-Sepharose, and specifically bound proteins eluted by competition with the 14-3-3-binding synthetic phosphopeptide, ARAApSAPA, as in \[[@RSOB140029C35]\] except that the high salt wash was only 500 ml and the mock peptide elution was omitted. The eluted proteins were denatured in 4× LDS sample buffer (Life Technologies) containing 10% sample reducing agent at 70°C for 10 min, cooled and alkylated with 50 mM iodoacetamide for 30 min in the dark at room temperature. Proteins were separated on NuPAGE 4--12% gradient gels and stained with colloidal Coomassie Blue (Life Technologies). Gel lanes were cut into 20 sections (electronic supplementary material, figure S6), which were washed successively with 50 mM triethylammonium bicarbonate; 50% acetonitrile, 50 mM triethylammonium bicarbonate (twice); and acetonitrile (15 min each wash), before drying in a SpeedVac (Eppendorf). Trypsin (5 μg ml^−1^ trypsin gold; Promega) in sufficient 25 mM triethylammonium bicarbonate to cover the gel pieces was added for 12 h at 30°C. Supernatant was transferred to a fresh tube, to which two 50% acetonitrile washes of the gel pieces were also added. The digested samples were dried, and each digest was redissolved in 2 μl of 25 mM sodium acetate buffer, pH 5.5, 30 mM sodium cyanoborohydride containing 0.2% (v/v) formaldehyde and incubated at room temperature for 15 min. Tryptic digests were analysed using Ultimate 3200 nanoflow chromatography (LC Packings) coupled to an LTQ-Orbitrap (Thermo Finnigan) mass spectrometer equipped with a dynamic NanoSpray source (Optron). For protein identification, mass spectra were acquired using the LTQ-Orbitrap programmed to perform two FT scans (60 000 resolution) on 300--800 and 800--1800 amu mass ranges with the top five ions from each scan selected for LTQ-MS/MS. FT spectra were internally calibrated using a single lock mass (445.1200 atomic mass units). Raw files were converted to peak lists in Mascot generic format (MGF) files using [raw]{.smallcaps}2[msm]{.smallcaps} v. 1.7 software (Matthias Mann) using default parameters and without any filtering, charge state deconvolution or deisotoping. MGF files were searched using a Mascot 2.2 in-house server against the International Protein Index human 3.26 database (57 846 sequences; 26 015 783 residues).
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